120 related articles for article (PubMed ID: 11418306)
1. The use of Shiga-like toxin 1 in cancer therapy.
Gariépy J
Crit Rev Oncol Hematol; 2001; 39(1-2):99-106. PubMed ID: 11418306
[TBL] [Abstract][Full Text] [Related]
2. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
3. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice.
LaCasse EC; Saleh MT; Patterson B; Minden MD; Gariépy J
Blood; 1996 Sep; 88(5):1561-7. PubMed ID: 8781410
[TBL] [Abstract][Full Text] [Related]
4. MHC class II proteins contain a potential binding site for the verotoxin receptor glycolipid CD77.
George T; Boyd B; Price M; Lingwood C; Maloney M
Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1179-85. PubMed ID: 11838965
[TBL] [Abstract][Full Text] [Related]
5. CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin.
Gordon J; Challa A; Levens JM; Gregory CD; Williams JM; Armitage RJ; Cook JP; Roberts LM; Lord JM
Cell Death Differ; 2000 Sep; 7(9):785-94. PubMed ID: 11042673
[TBL] [Abstract][Full Text] [Related]
6. Biochemical, pathological and oncological relevance of Gb3Cer receptor.
Đevenica D; Čikeš Čulić V; Vuica A; Markotić A
Med Oncol; 2011 Dec; 28 Suppl 1():S675-84. PubMed ID: 21069478
[TBL] [Abstract][Full Text] [Related]
7. Different binding property of verotoxin-1 and verotoxin-2 against their glycolipid receptor, globotriaosylceramide.
Itoh K; Tezuka T; Inoue K; Tada H; Suzuki T
Tohoku J Exp Med; 2001 Dec; 195(4):237-43. PubMed ID: 11908825
[TBL] [Abstract][Full Text] [Related]
8. An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo.
Cheung MC; Revers L; Perampalam S; Wei X; Kiarash R; Green DE; Abdul-Wahid A; Gariépy J
Mol Cancer; 2010 Feb; 9():28. PubMed ID: 20128926
[TBL] [Abstract][Full Text] [Related]
9. Probing the surface of eukaryotic cells using combinatorial toxin libraries.
Bray MR; Bisland S; Perampalam S; Lim WM; Gariépy J
Curr Biol; 2001 May; 11(9):697-701. PubMed ID: 11369233
[TBL] [Abstract][Full Text] [Related]
10. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.
Cohen A; Madrid-Marina V; Estrov Z; Freedman MH; Lingwood CA; Dosch HM
Int Immunol; 1990; 2(1):1-8. PubMed ID: 1965141
[TBL] [Abstract][Full Text] [Related]
11. Acquired Resistance to Shiga Toxin-Induced Apoptosis by Loss of CD77 Expression in Human Myelogenous Leukemia Cell Line, THP-1.
Hattori T; Watanabe-Takahashi M; Nishikawa K; Naito M
Biol Pharm Bull; 2018; 41(9):1475-1479. PubMed ID: 30175782
[TBL] [Abstract][Full Text] [Related]
12. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells.
Jacewicz MS; Acheson DW; Mobassaleh M; Donohue-Rolfe A; Balasubramanian KA; Keusch GT
J Clin Invest; 1995 Sep; 96(3):1328-35. PubMed ID: 7657808
[TBL] [Abstract][Full Text] [Related]
13. Shiga-like toxin I exerts specific and potent anti-tumour efficacy against gastric cancer cell proliferation when driven by tumour-preferential Frizzled-7 promoter.
Xu H; Peng L; Shen M; Xia Y; Li Z; He N
Cell Prolif; 2019 May; 52(3):e12607. PubMed ID: 30955216
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.
Mangeney M; Lingwood CA; Taga S; Caillou B; Tursz T; Wiels J
Cancer Res; 1993 Nov; 53(21):5314-9. PubMed ID: 8221667
[TBL] [Abstract][Full Text] [Related]
15. Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells.
Jarvis RM; Chamba A; Holder MJ; Challa A; Smith DC; Hodgkin MN; Lord JM; Gordon J
Biochem Biophys Res Commun; 2007 Apr; 355(4):944-9. PubMed ID: 17336267
[TBL] [Abstract][Full Text] [Related]
16. Verotoxin 1 from Escherichia coli affects Gb3/CD77+ bovine lymphocytes independent of interleukin-2, tumor necrosis factor-alpha, and interferon-alpha.
Menge C; Stamm I; Blessenohl M; Wieler LH; Baljer G
Exp Biol Med (Maywood); 2003 Apr; 228(4):377-86. PubMed ID: 12671182
[TBL] [Abstract][Full Text] [Related]
17. Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies.
Tam P; Mahfoud R; Nutikka A; Khine AA; Binnington B; Paroutis P; Lingwood C
J Cell Physiol; 2008 Sep; 216(3):750-63. PubMed ID: 18446787
[TBL] [Abstract][Full Text] [Related]
18. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3.
Ling H; Boodhoo A; Hazes B; Cummings MD; Armstrong GD; Brunton JL; Read RJ
Biochemistry; 1998 Feb; 37(7):1777-88. PubMed ID: 9485303
[TBL] [Abstract][Full Text] [Related]
19. Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells.
Brigotti M; Arfilli V; Carnicelli D; Rocchi L; Calcabrini C; Ricci F; Pagliaro P; Tazzari PL; Alfieri RR; Petronini PG; Sestili P
Toxins (Basel); 2013 Feb; 5(2):431-44. PubMed ID: 23430607
[TBL] [Abstract][Full Text] [Related]
20. Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia.
Lingwood CA
Biosci Rep; 1999 Oct; 19(5):345-54. PubMed ID: 10763802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
